Danyelza Prices, Coupons, Copay Cards & Patient Assistance
Danyelza (naxitamab) is a member of the miscellaneous antineoplastics drug class and is commonly used for Neuroblastoma.
The cost for Danyelza (gqgk 4 mg/mL) intravenous solution is around $27,836 for a supply of 10 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Danyelza prices
Intravenous Solution
gqgk 4 mg/mL
Danyelza intravenous solution
from $27,835.87
for 10 milliliters
Quantity | Per unit | Price |
---|---|---|
10 milliliters | $2,783.59 | $27,835.87 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Danyelza Coupons, Copay Cards and Rebates
Danyelza offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Danyelza Y-mAbs Connect Co-pay Program
Eligible commercially insured patients may pay $0 per infusion.
- Applies to:
- Danyelza
- Number of uses:
- 12 months from date of enrollment
Form more information phone: 833-339-6227 or Visit website
Patient Assistance & Copay Programs for Danyelza
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Y-mAbs Connect Patient Support Program
Eligibility requirements:- Must be uninsured or underinsured
- At or below 600% of FPL
- Medically Necessary as determined by a Doctor
- Must be residing in the US or US territory
- Co-payment assistance, patient support, and patient assistance programs are available for eligible patients.
- Danyelza (naxitamab-gqgk) Injection; IV
More information please phone: 833-339-6227 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Tavneos
Tavneos (avacopan) is a C5a receptor antagonist used for severe active ANCA-associated vasculitis ...
Platinol
Platinol is used for bladder cancer, blood cell transplantation, bone marrow transplantation, brain ...
Iwilfin
Iwilfin (eflornithine) is an oral ornithine decarboxylase inhibitor used to reduce the risk of ...
Oncovin
Oncovin is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Vincristine
Vincristine systemic is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Doxorubicin
Doxorubicin systemic is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder ...
More about Danyelza (naxitamab)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español